FDA Reports Improvement in Postmarket Drug Oversight - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Reports Improvement in Postmarket Drug Oversight


ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has detailed, in a new report, the agency’s objective to give postmarket drug-safety monitoring the same priority as premarket drug review. According to an FDA press release, the “strengthened and modernized postmarket drug program has resulted in a substantial improvement in…oversight of drugs once they reach the American public.” The report “Advances in FDA’s Safety Program for Marketed Drugs,” released on Apr. 21, 2012, gives an overview of FDA tools and capabilities used in the monitoring of postmarket drug safety. According to the report, drug-safety information is being communicated to the public faster than it has in the past, with the Center for Drug Evaluation and Research (CDER) issuing 68 drug-safety communications in 2011 compared to 39 in 2010.

In 2004, CDER introduced the new drug-safety plan, which was enhanced by the Food and Drug Administration Amendments Act (FDAAA) of 2007. FDAAA authorized changes to the safety monitoring of postmarket drugs and gave FDA the authority to require postmarket studies of drug-safety concerns and drug-labeling changes.

Since 2008, FDA’s postmarket monitoring program has required 65 safety-related labeling changes and has required manufacturers to implement risk evaluation and mitigation strategies. CDER has increased staff, established specific safety positions within new drug application divisions, and created the new Office of Biostatistics, which focuses on postmarket drug safety. FDA has also created drug-monitoring programs such as Safety First, Sentinel, and Safe Use. The Mini-Sentinel pilot project has enabled FDA to utilize access to electronic healthcare information nationwide.

“Our oversight of the safety of marketed drugs has changed significantly over the past few years,” said Janet Woodcock, MD, director CDER, in the press release. “This report shows that the quality, accountability, and timeliness of postmarket drug safety decisions have been enhanced, and our public communication of this information is more effective.”

See related articles:

FDA Updates Sentinel Initiative Status (ePT)

FDA Seeks More Timely Drug Information Electronically (BioPharm International)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here